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Objectives We investigated the functional relationship between natriuretic peptides and adiponectin by performing both
experimental and clinical studies.
Background Natriuretic peptides are promising candidates for the treatment of congestive heart failure (CHF) because of
their wide range of beneficial effects on the cardiovascular system. Adiponectin is a cytokine derived from adi-
pose tissue with various cardiovascular-protective effects that has been reported to show a positive association
with plasma brain natriuretic peptide (BNP) levels in patients with heart failure.
Methods The expression of adiponectin messenger ribonucleic acid (mRNA) and its secretion were examined after atrial
natriuretic peptide (ANP) or BNP was added to primary cultures of human adipocytes in the presence or absence
of HS142-1 (a functional type A guanylyl cyclase receptor antagonist). Changes of the plasma adiponectin level
were determined in 30 patients with CHF who were randomized to receive intravenous ANP (0.025 g/kg/min
human ANP for 3 days, n  15) or saline (n  15).
Results Both ANP and BNP dose-dependently enhanced the expression of adiponectin mRNA and its secretion, whereas
such enhancement was inhibited by pre-treatment with HS142-1. The plasma adiponectin level was increased at
4 days after administration of human ANP compared with the baseline value (from 6.56  0.40 g/ml to 7.34 
0.47 g/ml, p  0.05), whereas there was no change of adiponectin in the saline group (from 6.53  0.57 g/ml to
6.55  0.56 g/ml).
Conclusions Natriuretic peptides enhance adiponectin production by human adipocytes in vitro and even in patients with CHF,
which might have a beneficial effect on cardiomyocytes in patients receiving recombinant natriuretic peptide therapy
for heart failure. (J Am Coll Cardiol 2009;53:2070–7) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.038s
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rlasma natriuretic peptide levels are increased in patients
ith congestive heart failure (CHF), and the measurement
f these peptides is used widely to assess the presence,
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009, accepted February 19, 2009.everity, and prognosis of CHF (1,2). Both atrial natriuretic
eptide and brain natriuretic peptide (ANP and BNP,
espectively) have a beneficial effect in patients with heart
ailure because of their various biological actions (3–5).
See page 2078
Adiponectin is a circulating cytokine derived from adi-
ose tissue that has attracted considerable interest because
f its identification as a risk factor for cardiovascular disease
6,7) and CHF (8). Adiponectin production is down-
egulated in patients with coronary risk factors that are
ssociated with the development of heart failure (9,10).
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June 2, 2009:2070–7 BNP Enhances Adiponectin Productionecently, adiponectin was reported to have a cardioprotective
ffect against ischemia-reperfusion injury (11) and hemody-
amic stress (12,13) in mice. Interestingly, it has been reported
hat the level of N-terminal pro-brain natriuretic peptide
hows a positive correlation with the plasma adiponectin
oncentration in patients with chronic heart failure (14).
Given these experimental and clinical observations, we
ypothesized that natriuretic peptides might increase adi-
onectin production in patients with heart failure to protect
he cardiovascular system. Accordingly, in the present study,
e investigated whether natriuretic peptides could directly
ncrease adiponectin production by these adipocytes (and
he cellular mechanisms involved) and confirmed this effect
n adiponectin in the clinical setting.
ethods
gents. Both human ANP and BNP were purchased from
igma-Aldrich (St. Louis, Missouri). HS142-1, a func-
ional guanylyl cyclase-A type receptor antagonist, was
rovided by Kyowa Hakko Kogyo Co., Ltd. (Mishima,
apan). A cGMP analog (8-pCPT-cGMP) and a selective
GMP-dependent protein kinase G (PKG) inhibitor (Rp-
-Br-PET-cGMP-S) were obtained from Biolog Life Sci-
nce Institute (Bremen, Germany). An antibody directed
gainst mouse adiponectin (MAB3608) was purchased from
hemicon International, Inc.
rimary culture and in vitro study of human adipocytes.
ubcutaneous adipocytes derived from the adipose tissue of
women were obtained commercially together with culture
edium from Zen-Bio, Inc. (Research Triangle Park,
orth Carolina. The donors were nonsmokers with a mean
ody mass index of 27.0 kg/m2 (range 25.9 to 29.1 kg/m2)
nd an average age of 47 years (range 29 to 63 years). Cells
ere maintained in adipocytes maintenance medium (i.e.,
M-1) containing Dulbecco’s modified Eagle medium/
am’s F-12 (1:1, v/v), 3% fetal calf serum, 15 mmol/l
EPES (pH 7.4), biotin, pantothenate, human insulin, 1
mol/l dexamethasone, 100 U/ml penicillin, 100 g/ml
treptomycin, and 0.25 g/ml amphotericin B at 37°C in a
umidified atmosphere of 95% air/5% CO2. The medium
as changed every 2 days. Primary cultures of the adipocytes
ere used to examine the effects of natriuretic peptides
ANP or BNP) on the expression of adiponectin.
Before these experiments, the cells were plated in adipo-
yte basal medium (i.e., BM-1) containing Dulbecco’s
odified Eagle medium/Ham’s F-12 (1:1, volume/volume),
5 mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
cid (pH 7.4), biotin, and pantothenate for 24 h. Then the
ndicated concentrations of either natriuretic peptide (from
011 to 109 mol/l) were added to the BM-1 medium.
fter 24 h of incubation, the medium was harvested for
estern blotting to measure the secretion of adiponectin,
nd the cells were also harvested for ribonucleic acid
RNA) analysis. The effect of each natriuretic peptide on
diponectin messenger ribonucleic acid (mRNA) levels tas determined by quantitative
eal-time polymerase chain re-
ction (PCR).
easurement of adiponectin.
n patients with CHF, the plasma
diponectin concentration was
easured by the use of an ELISA
it (Otsuka Pharmaceutical Co.,
td., Tokyo, Japan) according to
he manufacturer’s protocol. Adi-
onectin secretion by primary cul-
ured human adipocytes was as-
essed by Western blotting of the
ulture medium, as previously de-
cribed (15), and the immunoreac-
ive bands were quantified by den-
itometry (Molecular Dynamics,
unnyvale, California).
everse transcriptional-PCR. Total RNA was extracted
rom adipocytes derived from human white fat with the
se of RNA-Bee-RNA Isolation Reagent (Tel-Test, Inc.,
ainesville, Florida). Then, 200 ng of total RNA was
eversed transcribed and amplified by the use of an Omniscript
T kit (Qiagen, Hilden, Germany) according to the manu-
acturer’s protocol. The forward primers for type A guanylyl
yclase receptor (GC-A) and natriuretic peptide receptor
NPR)-C were 5=-CCAGTTCCAAGTCTTTGCCAA-
ACAGCA and 5=-GGAAGACATCGTGCGCAATA,
espectively, and the reverse primers for GC-A and NPR-C
ere 5=-CATTGTGTAGAAACAGCATGCCCTTGA-
GA and 5=-TGCTCCGGATGGTGTCACT, respec-
ively. As a positive control, we used the samples of human
ardiac tissue under the protocol approved by the institu-
ional review board of the National Cardiovascular Center
No. 14-18) (16).
uantitative real-time PCR analysis. Quantitative real-
ime PCR was performed as described previously (17).
ligonucleotide primers and TaqMan probes for human
diponectin and glyceraldehyde 3-phosphate dehydrogenase
ere purchased from Applied Biosystems (Foster City,
alifornia).
ubjects and design of the clinical study. We prospec-
ively studied 30 consecutive CHF patients who were
dmitted to the emergency department of the National
ardiovascular Center between April and July 2006. The
xclusion criteria were as follows: age 80 years, cardio-
enic shock or hypotension (systolic blood pressure 100
m Hg), and renal failure (serum creatinine 2.0 mg/dl).
his study was approved by the Committee on Human
nvestigation of the National Cardiovascular Center, and all
atients who participated gave informed consent. The 30
atients were randomized to 2 groups, a human atrial
atriuretic peptide (hANP) group consisting of 15 patients
ho received administration of hANP and a control group
onsisting of 15 patients who were administered saline. In
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
BNP  brain natriuretic
peptide
CHF  congestive heart
failure
GC-A  type A guanylyl
cyclase receptor
hANP  human atrial
natriuretic peptide
NPR  natriuretic peptide
receptor
PKG  protein kinase Ghe hANP group, from immediately after the diagnosis of
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BNP Enhances Adiponectin Production June 2, 2009:2070–7cute exacerbation of CHF, hANP (0.025 g/kg/min) was
nfused intravenously for 3 days. The study protocol did not
estrict or specify any other diagnostic or therapeutic strat-
gies. Blood for measuring the plasma adiponectin level was
ampled before and 1 and 7 days after finishing the
dministration of hANP or saline (days 1, 4, and 10,
espectively) (Fig. 3A).
tatistical analysis. For analysis of differences between the
arious treatments of adipocytes, analysis of variance was
erformed, followed by the appropriate post-hoc test. The
ifferences in adiponectin levels between days 1 and 4 in
ach group were tested with a paired t test. The changes in
diponectin levels from day 1 to 4 between ANP group and
aline group was tested with an unpaired t test. Results are
xpressed as the mean  SEM, and p values of 0.05 were
onsidered significant.
esults
ffect of natriuretic peptides on the expression and
ecretion of adiponectin by primary cultured human
dipocytes. First, we checked the expression of GC-A and
PR-C mRNA by using reverse transcriptional-PCR. As
hown in Figure 1A, both GC-A and NPR-C mRNA was
etectable in primary cultured human adipocytes. To inves-
igate the effects of natriuretic peptides on the regulation of
diponectin production in adipocytes, we incubated primary
ultured human adipocytes with recombinant ANP. When
NP was used at a concentration of 1010 mol/l (patho-
ogical plasma concentration), it increased adiponectin
RNA expression after 6 h of incubation and reached a
aximum after 12 h (Fig. 1B). Next, we incubated human
dipocytes with ANP at the concentration of from 1011
ol/l (normal plasma concentration) to 109 mol/l (phar-
acological plasma concentrations) and demonstrated en-
anced adiponectin mRNA expression and adiponectin
ecretion into the medium in a dose-dependent manner,
hereas these changes were completely inhibited by pre-
reatment with HS142-1 (Figs. 1C and 1D). Incubation of
dipocytes with BNP also increased the expression of
diponectin mRNA in a dose-dependent manner and this
ffect was completely blocked by pretreatment with
S142-1 (Figs. 1E and 1F).
nvolvement of cGMP/PKG signaling in natriuretic
eptide-induced synthesis of adiponectin. Because both
NP and BNP exert their biological effects by promoting
GMP production, to investigate the role of the GC-A/
GMP/PKG signaling pathway in adiponectin production,
e measured the changes of cGMP in ANP-treated pri-
ary cultured human adipocytes. We found that incubation
ith ANP increased the cGMP level and that this effect was
lunted by co-treatment with HS142-1 (data not shown).
ext, we treated human adipocytes with the cGMP analog
-pCPT-cGMP and the PKG inhibitor (Rp)-8-Br-PET-
GMP-S. The activation of PKG by 8-pCPT-cGMP (50
mol/l for 12 h) produced an increase of adiponectin tRNA expression similar to that observed after incubation
ith ANP. The effect of ANP on adiponectin mRNA
xpression was abolished in the presence of (Rp)-8-Br-
ET-cGMP-S (100 nmol/l) (Fig. 2A). Consistent with
hese findings, adiponectin secretion into the culture me-
ium also was increased by stimulation of the cGMP/PKG-
ependent pathway (Fig. 2B). These results suggested that
atriuretic peptides promote adiponectin synthesis via the
C-A/cGMP/PKG-dependent pathway.
ncrease of plasma adiponectin levels in CHF patients
reated with hANP. To confirm the effect of natriuretic
eptides on the production of adiponectin, we conducted
he clinical study. Thirty consecutive patients who met the
nclusion criteria were enrolled in this clinical study. Fifteen
atients were randomized to the ANP group, and 15 were
ssigned to the saline group. Baseline variables and treat-
ents of the 2 groups are shown in Table 1. There were no
ifferences in baseline clinical characteristics, hemodynam-
cs, biochemical data, or medications. There was also no
ignificant difference in the baseline plasma level of adi-
onectin between the 2 groups. As shown in Figure 3B, the
lasma level of adiponectin did not change throughout the
tudy in the saline group. On the other hand, the plasma
diponectin level at 1 day after finishing the administration
f hANP (day 4) was significantly increased compared with
he baseline value (day 1) in the ANP group, and it returned
o baseline by 7 days after the completion of hANP infusion
day 10). These results suggested that hANP infusion led to
n increase of the plasma adiponectin level in patients with
HF.
iscussion
n the present study, we demonstrated a novel effect of
atriuretic peptides (ANP and BNP) on the production of
diponectin by adipocytes in both experimental and clinical
tudies. First, we clearly demonstrated that pathophysiolog-
cal and pharmacological concentrations of either ANP or
NP increased adiponectin synthesis by primary cultured
uman adipocytes. Second, we showed that administration
f recombinant ANP increased the plasma adiponectin level
n patients with CHF.
ANP and BNP play an important role in the regulation of
ardiovascular homeostasis. Their actions are primarily me-
iated via GC-A, which is expressed in various tissues and
rgans, including the kidneys, blood vessels, adrenal glands,
nd heart (18). Consistent with a previous report (19), we
emonstrated that GC-A and NPR-C are expressed by
uman adipocytes. In the present study, we demonstrated a
ovel effect of both ANP and BNP on primary cultured
uman adipocytes, which was that pathophysiological or
harmacological concentrations of both peptides augmented
diponectin production by human adipocytes, with this
ffect being inhibited by treatment with HS142-1. Further-
ore, we demonstrated that natriuretic peptides augmenthe production of adiponectin via a cGMP-dependent
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June 2, 2009:2070–7 BNP Enhances Adiponectin Productionathway. These findings are important evidence that
NP and BNP regulate adiponectin production by hu-
an adipocytes.
Intravenous infusion of nesiritide (recombinant human
Figure 1 Effect of Natriuretic Peptides on the Expression and S
(A) Expression of GC-A receptors (top) and NPR-C (bottom) mRNA by primary cult
receptors and NPR-C by human adipocytes. (B) Effect of ANP (1010 mol/l) o
(C) Dose-dependent effect of ANP on adiponectin mRNA expression, as determine
centrations of ANP for 24 h. (D) Dose-dependent effect of ANP on adiponectin sec
(Bottom) Quantitative analysis of adiponectin by densitometry. Values are normali
(E) Dose-dependent effect of BNP on adiponectin mRNA expression, as determine
secretion into the culture medium as determined by Western blotting. (Top) Repre
densitometry. Values are normalized to the control. *p  0.05 versus control. †p
uretic peptide; GC-A  type A guanylyl cyclase receptor; mRNA  messenger ribonNP) has been reported to have beneficial hemodynamic offects in patients with CHF (4,5). The use of ANP also has
een reported to have beneficial effects in patients with
cute myocardial infarction (20,21). These beneficial effects
ave been attributed to the cardiovascular-protective actions
tion of Adiponectin by Primary Human Adipocytes
uman adipocytes. Reverse-transcription PCR revealed expression of both GC-A
expression of adiponectin mRNA as determined by quantitative real-time PCR.
uantitative real-time PCR. Human adipocytes were treated with the indicated con-
into the culture medium. (Top) A representative Western blot of adiponectin.
the control. *p  0.05 versus control, †p  0.05 versus ANP 109 mol/l.
uantitative real-time PCR. (F) Dose-dependent effect of BNP on adiponectin
ive Western blot of adiponectin. (Bottom) Quantitative analysis of adiponectin by
5 versus BNP 109 mol/l. ANP  atrial natriuretic peptide; BNP  brain natri-
acid; NPR-C  natriuretic peptide receptor C; PCR  polymerase chain reaction.ecre
ured h
n the
d by q
retion
zed to
d by q
sentat
 0.0
ucleicf natriuretic peptides, including diuresis, natriuresis, vaso-
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BNP Enhances Adiponectin Production June 2, 2009:2070–7ilation, and reduction of activity of the sympathetic ner-
ous system and the renin-angiotensin-aldosterone system
3–5). In the present study, we administered recombinant
NP to patients with CHF and observed the changes of
lasma adiponectin. The plasma adiponectin level of the
NP group was increased at 1 day after the finish of ANP
dministration compared with that in the control group,
nd then returned to baseline by 7 days after the completion
f administration in patients with CHF.
Importantly, Moro et al. (22) showed that ANP did not
ffect the secretion of adiponectin in human abdominal
Figure 2 Involvement of the cGMP/PKG Signaling Pathway in t
(A, B) Involvement of PKG was assessed by the treatment of primary cultured hum
Adiponectin mRNA levels were determined by quantitative real-time PCR (A) and s
Quantitative analysis of adiponectin secretion into the culture medium was done b
†p  0.05 versus ANP. HS  HS142-1; other abbreviations as in Figure 1.
Clinical Characteristics of the 2 Groups
Table 1 Clinical Characteristics of the 2 Gro
hANP Group
Age (yrs) 60
Sex (male/female) 9/6
Heart rate (beats/min) 62
Body mass index (kg/m2) 21.4
Systolic blood pressure (mm Hg) 116
Diastolic blood pressure (mm Hg) 76
NYHA functional class (II/III) 14/1
LVEF by echocardiography (%) 32
Plasma BNP (pg/ml) 506
Other medications n (%)
Loop diuretics 9 (60
Spironolactone 5 (33
ACEI or ARB 12 (80
Beta-blockers 13 (86ACEI  angiotensin-converting enzyme inhibitors; ARB  angiotensin II recep
natriuretic peptide; LVEF  left ventricular ejection fraction; NS  not significdipose tissue from overweight women. This result may
ppear contradict ours, but we believe that is not the case.
irst, the concentration of ANP they used (106 mol/l) in
he experiment of cultured adipocytes was greater than our
oncentration. Second, our data that recombinant ANP
ncreased the plasma adiponectin levels were drawn from
atients with heart failure, whereas the data of Moro et al.
22) were from cultured fat tissues of overweight women
ho underwent plastic surgery. However, they also demon-
trated the potential stimulatory effect of ANP on adiponec-
in production from human adipose tissue in the presence of
duction of Adiponectin Synthesis by ANP
ipocytes with 8-pCPT-cGMP (8-pCPT) and (Rp)-8-Br-PET-cGMP-S (Rp-8-pCPT).
n of adiponectin into the culture medium was determined by Western blotting.
itometry (B). Values are normalized to the control. *p  0.05 versus control.
5) Saline Group (n  15) p Value
59 19 NS
10/5 NS
66 7 NS
21.1 1.7 NS
113 9 NS
74 6 NS
10/5 NS
31 8 NS
537 33 NS
10 (67) NS
8 (53) NS
11 (80) NS
12 (80) NShe In
an ad
ecretio
y densups
(n  1
19
11
1.1
9
12
2
39
)
)
)
)tor blockers; BNP  brain natriuretic peptide; hANP  human atrial
ant; NYHA  New York Heart Association.
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June 2, 2009:2070–7 BNP Enhances Adiponectin Productionormone-sensitive lipase inhibitor, which inhibits the for-
ation of lipolysis-derived byproducts by ANP-induced
ipolysis (22).
Recently, Yu et al. (23) demonstrated the increased
NP-induced lipolysis rates in large adipocytes compared
ith small adipocytes. Thus, the difference of adipocyte size
etween patients with CHF and obesity might contribute to
he different pattern of adiponectin secretion. Finally, cat-
cholamines also are involved in the control of lipolysis in
umans (24). Thus, the prolonged exposure of high plasma
evel of catecholamines or the treatment with beta-
drenergic receptor blockers in patients with CHF also
ight affect the distinct pattern of adiponectin secretion
rom adipocytes. Although precise mechanisms are un-
nown, the human adipocytes could secrete adiponectin
hen the certain stress was loaded. However, it remains
Figure 3 Increased Plasma Adiponectin Level in Patients With
(A) Outline of the study protocol. hANP or saline was infused continuously for 3 da
of either hANP (0.025 g/kg/min) or saline. (B) The plasma adiponectin concentr
group; †p  0.05 versus at the corresponding time in the saline group. CHF  co
in Figure 1.ossible that factors such as tumor necrosis factor-alpha (25) ond alpha-adrenergic stimulation (26), both of which are
ncreased in patients with CHF, may influence the expres-
ion of adiponectin or that adiponectin levels are affected by
edical treatment, so further investigations are needed.
It is not clear whether ANP augments the plasma
diponectin levels in healthy subjects because of the ethical
roblems. However, we have reported that the plasma
diponectin level increased along with an increase of plasma
NP levels in 1,538 healthy subjects (27). These results
uggest that an increase of natriuretic peptides augments the
lasma adiponectin levels and exerts a cardioprotective effect
n clinical settings.
Under normal conditions the adult heart utilizes predom-
nantly fatty acids to derive the majority of its energy (28).
owever, metabolic remodeling such as a marked shift in
ubstrate preference away from fatty acids toward glucose is
After ANP Treatment
the ANP and saline groups, respectively. The black bar indicates administration
rofile after treatment in both groups. *p  0.05 versus baseline in the ANP
ve heart failure; hANP  human atrial natriuretic peptide; other abbreviations asCHF
ys in
ation p
ngestibserved in hypertrophic and failing hearts and the decrease
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BNP Enhances Adiponectin Production June 2, 2009:2070–7n fatty acid oxidation is not fully compensated for by an
ncrease in glucose oxidation (29). Thus, the failing heart
uffers from chronic energy starvation (30). Insulin resis-
ance also is common in patients with heart failure (31).
diponectin improves both glucose metabolism and insulin
esistance via the AMPK signaling pathway (32). Therefore,
e believe that the administration of recombinant natri-
retic peptide has beneficial effects on cardiac energy me-
abolism via adiponectin in patients with CHF.
Interestingly, the plasma adiponectin level was re-
orted to be decreased in patients with risk factors for
eart failure (9,33–35) and increased along with BNP
fter the onset of heart failure (14). Although approxi-
ately 10% increase in adiponectin levels in the ANP
roup seems relatively small, this would not be the case
ecause there was about a 20% reduction in plasma
diponectin levels in patients with coronary artery disease
ompared with those in control subjects (35), which leads
s to believe that the 10% increase in adiponectin is
mportant from the viewpoint of pathophysiology of
eart diseases. Therefore, we hypothesized that ANP
nd/or BNP regulates the plasma level of adiponectin in
atients with CHF and conducted this study.
onclusions
e demonstrated that natriuretic peptides increase the
roduction of adiponectin by human adipocytes, as well as
n patients with CHF. These findings may help to shed
ore light on the pathophysiology of heart failure.
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